Home Daily Stock Opinions and Ratings Novo-Nordisk (NVO-N)

Trending stocks today

iShares Barclays 20+ Yr Treas Bond BETAPRO SP500 DAILY INVERSE ETF BMO S&P/TSX Oil & Gas ETF BMO EQUAL WEIGHT BANKS INDEX ETF Amazon.com Raytheon Whitecap Resources IBM Chevron Texaco Sunrun Inc. Amazon.com Apple Inc Alphabet Inc. / Google Artis Real Estate Investment Trust Canadian Imperial Bank of Commerce (CIBC) Cogeco Communications Athabasca Oil Sands Corp Tamarack Valley Energy Baytex Energy Corp

Novo-Nordisk (NVO-N)

102 watching

NYSE:NVO

138.09
0.55 (0.40%) 1d
Jan 27, 2023, 9:00 pm
0
COMMENT

Novo-Nordisk(NVO-N)

12/12/2022
Novo-Nordisk
The stock is up so much, but they produce the right medical products.
biotechnology / pharmaceutical
Jim Cramer - Mad Money
$129.430
Unknown
UnlockRating
BUY

Novo-Nordisk(NVO-N)

17/06/2022
Novo-Nordisk
Likes company and has owned shares for a long time. #1 company in European diabetic market. Share prices are a little over priced. Will continue holding shares for the long term.
biotechnology / pharmaceutical
Darren Sissons
$105.580
Owned
UnlockRating
WEAK BUY

Novo-Nordisk(NVO-N)

12/05/2022
Novo-Nordisk
NVO vs. LLY Focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
biotechnology / pharmaceutical
Paul MacDonald
$104.480
No
UnlockRating
PAST TOP PICK

Novo-Nordisk(NVO-N)

04/02/2022
Novo-Nordisk
(A Top Pick Feb 10/21, Up 46%) Believes company is leading insulin producer for diabetics. Revenues outside USA are increasing. Above average financial results from previous quarter was rewarded by market. Rising diabetes levels in society will be good for company. Company has very little debt and is looking at other products.
biotechnology / pharmaceutical
David Driscoll
$99.670
Owned
UnlockRating
COMMENT

Novo-Nordisk(NVO-N)

17/01/2022
Novo-Nordisk
He was negative on this 5 years ago but now likes it and owns some for the long term. Insulin prices have normalized and it has a good weight loss drug. When asked to compare to Lilly he prefers NVO although Lilly is good too. The only concern is that this is a defensive growth stock and some might sell to buy cyclicals.
biotechnology / pharmaceutical
David Fingold
$96.320
Owned
UnlockRating
PAST TOP PICK

Novo-Nordisk(NVO-N)

08/10/2021
Novo-Nordisk
(A Top Pick Feb 10/21, Up 49%) Leading company for making insulin. The FDA approved their 2.5mg dose of weight-loss drug, which helped share prices. They are first to market with it. The expectations for earnings were moved higher. Getting more international sales in the long term. Stock is starting to get noticed by fund managers internationally.
biotechnology / pharmaceutical
David Driscoll
$98.380
Owned
UnlockRating
BUY

Novo-Nordisk(NVO-N)

31/08/2021
Novo-Nordisk
A Danish drug company that makes insulin. He likes the pharma stocks, though have been underperforming. He owns many pharmas, but you can't own all of them.
biotechnology / pharmaceutical
Norman Levine
$100.380
No
UnlockRating
HOLD

Novo-Nordisk(NVO-N)

17/06/2021
Novo-Nordisk
Largest producer of insulin in the world. Diabetes is one of the fastest-growing diseases. Will continue to do well.
biotechnology / pharmaceutical
Paul Harris, CFA
$82.630
Owned
UnlockRating
TOP PICK

Novo-Nordisk(NVO-N)

07/06/2021
Novo-Nordisk
A long time favourite. Recent news was FDA approval of a diabetes drug that can also be used for weight-loss. (Analysts’ price target is $76.50)
biotechnology / pharmaceutical
David Driscoll
$81.210
Owned
UnlockRating
TOP PICK

Novo-Nordisk(NVO-N)

10/02/2021
Novo-Nordisk
Take a pill once a week instead of injecting. Big implications moving forward. International sales have gone beyond what US sales were. Good entry point for the next 5-10 years. May get more diversified over time. No debt outstanding. Yield is 1.45% (Analysts’ price target is $75.73)
biotechnology / pharmaceutical
David Driscoll
$71.220
Owned
UnlockRating
COMMENT

Novo-Nordisk(NVO-N)

20/10/2020
Novo-Nordisk

It's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.

biotechnology / pharmaceutical
Paul MacDonald
$71.480
No
UnlockRating
BUY

Novo-Nordisk(NVO-N)

14/09/2020
Novo-Nordisk
The largest maker of insulin in the world. They have a strong diabetes franchise. Type diabetes is growing incredibly quickly around the world. They are one of the few companies that are involved in Diabetes. He thinks it will continue to accelerate and why this one will do well. It is a great story at 21 times earnings and 2% dividend yield. He will continue to buy it.
biotechnology / pharmaceutical
Paul Harris, CFA
$66.725
Owned
UnlockRating
BUY

Novo-Nordisk(NVO-N)

25/08/2020
Novo-Nordisk
If The Democrats Their goal is to sell outside the U.S. which they have done successfully, which have increased revenues, profits and dividends. Most importantly, their pill will replace people with type 2 diabetes from injecting insulin and helps people lose weight. They are the biggest insulin-maker in the world. This will be a big mover in coming years in pharma. You can take profits if the stock has moved up and is outsized in your portfolio.
biotechnology / pharmaceutical
David Driscoll
$66.295
Owned
UnlockRating
PAST TOP PICK

Novo-Nordisk(NVO-N)

20/08/2020
Novo-Nordisk
(A Top Pick Sep 26/19, Up 29%) Diabetes and hemophilia. Diabetes continues to grow. NVO is at the sweet spot of that. Obesity will become a bigger and bigger issue.
biotechnology / pharmaceutical
Paul Harris, CFA
$66.440
Owned
UnlockRating
PAST TOP PICK

Novo-Nordisk(NVO-N)

21/07/2020
Novo-Nordisk
(A Top Pick Aug 15/19, Up 38%) The biggest producer of insulin in the world. Type 2 diabetes is rapidly growing which helps NVO's growth. Very well-run. They have an obesity drug. A great demographic story. He continues to like it. He'd buy it here.
biotechnology / pharmaceutical
Paul Harris, CFA
$68.765
Owned
UnlockRating
Showing 1 to 15 of 98 entries
Next PageNext Page

Novo-Nordisk(NVO-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 3 stock analysts published opinions about NVO-N. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

3 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2023-01-27, Novo-Nordisk (NVO-N) stock closed at a price of $138.09.

You may also like:

RAR-X APQ-T QXM-T BAN-T RES-T AVT-Q PRPL-Q MGNI-Q BEC-N EVLLF-O

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

AAP-NAdvance Auto Parts
Advance Auto Parts
$147.44
-0.18 (-0.12%)
LHX-NL3Harris Technologies
L3Harris Technologies
$212.10
15.56 (6.83%)
SNOW-NSnowflake
Snowflake
$159.36
6.91 (4.16%)
NET-NCloudflare
Cloudflare
$53.11
3.59 (6.33%)
SBUX-QStarbucks
Starbucks
$109.02
0.26 (0.24%)
Advertising

Today's Top Picks

BTE-TBaytex Energy Corp
Baytex Energy Corp
$6.16
0.21 (3.30%)
TVE-TTamarack Valley Energy
Tamarack Valley Energy
$4.79
0.14 (2.84%)
ATH-TAthabasca Oil Sands Corp
Athabasca Oil Sands Corp
$2.69
0.17 (5.94%)
CCA-TCogeco Communications
Cogeco Communications
$68.74
0.40 (0.58%)
CM-TCanadian Imperial Bank of Commerce (CIBC)
Canadian Imperial Bank of Commerce (CIBC)
$59.47
0.69 (1.15%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

NET-NCloudflare
Cloudflare
$53.11
3.59 (6.33%)
UPS-NUnited Parcel Services
United Parcel Services
$182.09
2.39 (1.30%)
INTC-QIntel
Intel
$28.16
-1.93 (-7.36%)
PEY-TPeyto Exploration & Develop.
Peyto Exploration & Develop.
$13.02
-0.04 (-0.31%)
BMW-GRBayerische Motoren Werke AG
Bayerische Motoren Werke AG
$92.94
0.59 (0.63%)

Most Recent Experts

Nuttall

Eric Nuttall

Ninepoint Partners

Stockchase

Stockchase Insights

5i Research

Cramer

Jim Cramer - Mad Money

CNBC

Harris

Paul Harris, CFA

Harris Douglas Asset Management

Panic-Proof (Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.